4//SEC Filing
Weber Barbara 4
Accession 0001610717-23-000260
CIK 0001628171other
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 8:03 PM ET
Size
12.0 KB
Accession
0001610717-23-000260
Insider Transaction Report
Form 4
Weber Barbara
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-09-01−11,146→ 1,851 totalExercise: $4.73From: 2022-02-09Exp: 2029-08-08→ Common Stock (11,146 underlying) - Exercise/Conversion
Common Stock
2023-09-01$4.73/sh+11,146$52,721→ 30,825 total - Sale
Common Stock
2023-09-01$35.07/sh−15,000$526,001→ 15,825 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-01−3,854→ 9,635 totalExercise: $1.12From: 2022-04-20Exp: 2028-04-19→ Common Stock (3,854 underlying) - Exercise/Conversion
Common Stock
2023-09-01$1.12/sh+3,854$4,316→ 19,679 total
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022.
- [F2]Includes 5,200 restricted stock units.
- [F3]The transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001800670
Filing Metadata
- Form type
- 4
- Filed
- Sep 5, 8:00 PM ET
- Accepted
- Sep 6, 8:03 PM ET
- Size
- 12.0 KB